The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
about
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetesRenoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats.Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trialSodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Adverse Effects Associated With Newer Diabetes Therapies.Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease.Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.LncRNAs: key players and novel insights into diabetes mellitus.Diabetic kidney disease.High glucose/lysophosphatidylcholine levels stimulate extracellular matrix deposition in diabetic nephropathy via platelet‑activating factor receptor.Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.[Diabetic kidney disease - Update 2016].
P2860
Q26749281-37C0DD94-E62F-4C05-A5EF-24BDA3B9CF00Q36004330-3129E40E-8A42-491C-93CE-6DE4E9735364Q36820255-511F87C6-1AE8-44FE-81F6-9B38F11B840FQ37722896-142C35DB-2EBE-4592-9C24-2FA6850CEDEBQ38546214-D8E7B40B-CA93-43CD-AEA9-C5B1C47C9B89Q38640778-21B909CE-0A20-4244-976A-020355F1235CQ38878430-CA306005-2CA6-4BF7-8F9C-609AEFD40731Q40873693-FDF05788-B33A-46C8-A0A8-23533674ED71Q42378533-8F8A831E-3FFC-4513-9543-15FADBDE066DQ43721013-F2866722-C05B-43AF-8DCB-D0DA67367E86Q47329024-D1E4D9A7-7980-4F14-AAE9-DE579D53AF43Q52594764-EE9841BD-5B47-4EFE-8A0C-6AC3D251BE23Q53620509-84279D86-0E93-468E-BB90-8822936A94CA
P2860
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@ast
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@en
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@nl
type
label
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@ast
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@en
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@nl
prefLabel
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@ast
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@en
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@nl
P2093
P2860
P921
P356
P1476
The effects of GLP-1 analogues ...... nhibitors on the renal system.
@en
P2093
Carl Erik Mogensen
Gerit-Holger Schernthaner
Guntram Schernthaner
P2860
P304
P356
10.1177/1479164114542802
P407
P5008
P577
2014-09-01T00:00:00Z